Le développement des neurosciences nous permet de commencer à mieux comprendre le fonctionnement du cerveau humain et ses aptitudes. Il n'élimine pas, pour autant, les croyances et les mythes sur les pouvoirs cachés de notre encéphale. Elena Pasquinelli vient de publier un livre primé et édifiant qui se charge de corriger ces erreurs et de nous montrer que nous avons tout intérêt à nous méfier de certaines perceptions. Nous en débattons dans le Club Science publique.
Bad press didn’t hurt Sovaldi™ (sofosbuvir) after all. The Hepatitis C virus (HCV) treatment drew the wrath of three members of Congress, who demanded that developer Gilead Sciences justify its $84,000 price for a full 12-week treatment course of Sovaldi. The company offered its justification and didn’t have to worry about too much fallout from the criticism, since its three Congressional critics were top Democrats in the Republican-majority House of Representatives.
Even better for Gilead, which barely began marketing Sovaldi at the end of 2013, sales of the HCV treatment zoomed into eight figures—high enough to place near the top of GEN’s latest version of its List of Top 25 Best-Selling Drugs, reflecting drug sales reported for 2014.
Unlike last year’s Top 25 Best-Selling Drugs of 2013, this year’s list had only 24 drugs generating total sales of $3 billion or more. That allowed the 25th best-selling drug of 2014 to make this year’s list (it appeared in GEN’s Top 20 Best-Selling Drugs list in 2012 but missed 2013), despite sales in only the high-$2 billion range.
Biopharma is in a transition period as the blockbusters of the past decade fade. They have either fallen off the proverbial patent cliff (Novartis’ Diovan, which lost US exclusivity in 2012) or succumbed to a stronger U.S. dollar against European and Asian currencies despite rising sales (Novo Nordisk’s NovoLog, which also missed this year’s list). At the same time, the next generation of multi-billion-dollar drugs takes time to build the billions in sales needed to make the best-seller list—but can be expected to do so starting next year.
At the top, last year’s winner finished #1 again, and with higher sales than 2013. Indeed more than half (16) of the Top 25 best-selling drugs did better in 2014 than the previous year. Among the top three disease categories, six best-selling drugs have indications for forms of cancer, and five for arthritis. Five indications—asthma/COPD, diabetes, heart disease, HIV, and multiple sclerosis—are each represented on the list by two best sellers.
One likely top-seller of 2014 not on the list is Boehringer Ingelheim’s Spiriva, which racked up €3.552 billion ($4.019 billion) in 2013. However, BI will not release full-year 2014 data until April 22, just as it waited until April 2014 to release 2013 data, explaining its absence from GEN’s list.
The software industry experienced 4.8% growth in 2013, and Microsoft remains the world’s top software company. (The software industry experienced 4.8% growth in 2013, and @Microsoft remains the world’s top software company.
Pharma, Biotechnology, Biobanks, Research & Quality Control Agenda on February 26th, 2014 in Budapest, Hungary.
Gretel Posadas's insight:
From February 25th until 27th 2014
FRANCELAB SCIENTIFIC CONFERENCE DAYS
at the French Institute of Budapest, Hungary
Fö utca 17 (metro : BATTHYANY tér)
Agenda on February 26th, 2014 :
9.10 Sylvette Tourmente: Attachée de coopération scientifique, technique et universitaire à l’Ambassade de France en Hongrie: French - Hungarian research collaboration opportunities.
9.35 Romain BRUDER - HORIBA JOBIN YVON: «FLIM and nanoparticle- enhanced fluorescence, powerful tools for #Biotech applications of lifetime fluorescence»
10.00 BICZÓK László: MTA TTK - Molekuláris Farmakológiai Intézet: «Interaction of alkaloid and #macrocyclic compound studied by fluorescence methods»
10.25 HORNOK Viktória, BENKŐ Mária, DÉKÁNY Imre: SZEGEDI TUDOMÁNYEGYETEM - Kolloidkémiai Tanszék: «Dynamic light scattering for the determination of particle size distribution and z-potential of nanoparticles. Special applications in the 2-20 nm range with Horiba SZ-100.»
10.50 - Coffee Break
11.05 Michel DEPONT - CRYO BIO SYSTEM: «High Security #Biobanking Solution»
11.30 #Gretel POSADAS - #BIOSAMPLING SYSTEMS: «BioSampling Systems combines speed and high capacity to improve the #storage quality of sample management in biobanks, hospitals and blood transfusion centers»
11.55 Claude SIGWALT - ACTINI: «Effluents treatment in Biosafety labs»
12.20 - Lunch break
13.00 Stephan MOREAU - SETARAM: «μSC a new tool for #Pharmaceuticals and Biotech applications»
13.25 GYURCSÁNYI Róbert - BME Szervetlen és Analitikai Kémia Tankszék: «SPR imaging for the characterization of synthetic receptors.»
13.50 Romain BRUDER - HORIBA JOBIN YVON: «#Raman #spectoscopy for biological and pharmaceutical samples – a review of specific tools»
14.15 Sylvain MOREL - ALPHA MOS: «How to measure the taste without human tongue? the use of E-Tongue in Pharma #applications»
Reconstructing the rise of life during the period of Earth's history when it first evolved is challenging. Earth's oldest sedimentary rocks are not only rare, but also almost always altered by hydrothermal and tectonic activity.
(Medical Xpress)—Could a drug commonly prescribed to prevent bone loss boost the power of #vaccines?
New research from Harvard Medical School shows that adding compounds known as bisphosphonates to both commercial and experimental vaccines enhances their effectiveness in mice, raising hopes they could help people mount a more robust #immune response.
Textbook makers, bookstore owners and college student surveys all say millennials still strongly prefer print for pleasure and learning, a bias that surprises reading experts given the same group’s proclivity to consume most other content digitally. A University of Washington pilot study of digital textbooks found that a quarter of students still bought print versions of e-textbooks that they were given for free.
“These are people who aren’t supposed to remember what it’s like to even smell books,” said Naomi S. Baron, an American University linguist who studies digital communication. “It’s quite astounding.”
A recipe detailing how to make extraordinary stem cells from ordinary cells—just by "stressing" them with acid—will "soon" be posted for all to try, says Riken. This could settle much controversy surrounding the cells...or spur more.
Munich, January 31, 2014 - Icon Genetics GmbH (ICON) successfully completed a Phase I clinical study on the safety and immunogenicity of personalized vaccines to treat patients with follicular non-Hodgkin's lymphoma. The vaccines, which consist of monoclonal antibodies derived from each patient's own tumor and serve as disease-specific markers, were administered to induce a tumor-specific immune reaction. The vaccines were manufactured in tobacco plants using magnICON® technology in the facility owned and operated by ICON in Halle, Germany. Results of the 27-patient study demonstrated the safety, tolerability and tumor-specific immunogenicity of the plant-made vaccines. #Cancer patients receiving ICON's vaccines did not exhibit the types of side effects that are typically associated with more traditional approaches for cancer treatment. Thus, these vaccines have the potential of offering patients improved quality of life throughout their therapeutic regimen. While not designed to assess efficacy, the study evaluated immune responses to vaccination. Of the patients evaluated at study completion, 73% were found to have mounted a tumor-specific immune response. The Phase I trial was sponsored by Bayer Innovation GmbH and conducted under US FDA IND at 3 clinical centers in the United States, with primary treatment at the University of Texas Southwestern Medical Center and Baylor Medical Center, both in Dallas, Texas, with local coordination and oversight provided by DAVA Oncology, LP.
Would you like to become a professional on #NEO SAMPLE MANAGEMENT automate?
BioSampling Systems would like to invite you to the exclusive #training about the innovative technology behind this fantastic liquid handling robot.
Join us in our training #sessions from March 6th, 2014 until May 30th 2014: 1st Training session: Monday March 17th, 2014 2nd Training session: Monday April 21st, 2014 3rd Training session: Monday May 19th, 2014
Yes, You would like to assist to NEO Training contact us at email@example.com Object : NEO SAMPLE MANAGEMENT TRAINING
Trophic cascade effects occur when a food web is disrupted by loss or significant reduction of one or more of its members. In East African Rift Valley lakes, the Lesser Flamingo is on top of a short food chain. At irregular intervals, the dominance of their most important food source, the cyanobacterium Arthrospira fusiformis, is interrupted. Bacteriophages are known as potentially controlling photoautotrophic bacterioplankton. In Lake Nakuru (Kenya), we found the highest abundance of suspended viruses ever recorded in a natural aquatic system. We document that cyanophage infection and the related breakdown of A. fusiformis biomass led to a dramatic reduction in flamingo abundance. This documents that virus infection at the very base of a food chain can affect, in a bottom-up cascade, the distribution of end consumers. We anticipate this as an important example for virus-mediated cascading effects, potentially occurring also in various other aquatic food webs.
BioSampling Systems and our French Vendor "DAY medical" are having a great time with our customers of 3S System and SSP Plate 48 at JIB 2013. Today is our last day come and visit our stand ! For more information about our liquind handling options visit : www.biosamplingsystems.com
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.